What amount sold does VOLITIONRX LTD report in Form D filings?

The latest linked filings report $51.6M sold across 14 identified offering(s). 1 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was VOLITIONRX LTD's most recent SEC filing?

VOLITIONRX LTD's most recent Form D filing was on 2026-01-28.

How many investors does VOLITIONRX LTD have?

The most recent Form D filing lists 1 investor(s).

VOLITIONRX LTD

VNRX

CIK: 0000093314·Biotechnology·Henderson, NV

Reported Sold

$51,607,812

Total Filings

Identified Offerings

Last Filed

Jan 28, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 1 unlinked amendment excluded.

Offering filing timeline

Jan 28, 2026Form D/A — Amendment

Reported sold: $22,650,000 · Target: $22,650,000

No verified predecessor available.

Rule 506(b)·1 investor

May 30, 2025Form D — New notice

Reported sold: $16,250,000 · Target: $16,250,000

Rule 506(b)·1 investor

Mar 26, 2024Form D — New notice

Reported sold: $100,000 · Target: $100,000

Rule 506(b)·1 investor

Aug 27, 2018Form D — New notice

Reported sold: $24,000,000 · Target: $24,000,000

Rule 506(b)·1 investor

Nov 21, 2014Form D — New notice

Reported sold: $721,849 · Target: $721,849

Rule 506(b)·21 investors

Oct 14, 2014Form D — New notice

Reported sold: $750,000 · Target: $750,000

Rule 506(b)·23 investors

Oct 14, 2014Form D — New notice

Reported sold: $229,393 · Target: $229,393

Rule 506(b)·10 investors

Sep 25, 2014Form D — New notice

Reported sold: $1,189,749 · Target: $1,189,749

Rule 506(b)·7 investors

Mar 11, 2014Form D — New notice

Reported sold: $3,000,000 · Target: $3,000,000

Rule 506(b)·24 investors

Dec 3, 2013Form D — New notice

Reported sold: $934,923 · Target: $1,000,000

Rule 506(b)·7 investors

Jun 14, 2013Form D — New notice

Reported sold: $595,000 · Target: $1,500,000

Rule 506·27 investors

May 8, 2013Form D — New notice

Reported sold: $416,000 · Target: $500,000

Rule 506·8 investors

Mar 27, 2013Form D — New notice

Reported sold: $489,583 · Target: $500,000

Rule 506·19 investors

Jul 26, 2012Form D — New notice

Reported sold: $1,204,152 · Target: $3,000,000

Rule 506·33 investors

Oct 28, 2011Form D — New notice

Reported sold: $1,727,163 · Target: $1,727,163

Rule 506·38 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$288,889

Amendment Rate

Latest reported sold across 14 identified offerings

$51,607,812

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

1 unlinked amendment excluded.

Key People

Cameron Reynolds

Related Person

Appears on 10 filings

ALAN COLMAN

Related Person

Appears on 10 filings

MARTIN FAULKES

Related Person

Appears on 9 filings

RODNEY GERARD ROOTSAERT

Related Person

Appears on 9 filings

GUY ARCHIBALD INNES

Related Person

Appears on 6 filings

Habib Skaff

Related Person

Appears on 5 filings

MALCOLM LEWIN

Related Person

Appears on 5 filings

Mike O'Connell

Related Person

Appears on 4 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jan 28, 2026	Amendment	$22,650,000	$22,650,000	1
May 30, 2025	New	$16,250,000	$16,250,000	1
Mar 26, 2024	New	$100,000	$100,000	1
Aug 27, 2018	New	$24,000,000	$24,000,000	1
Nov 21, 2014	New	$721,849	$721,849	21
Oct 14, 2014	New	$229,393	$229,393	10
Oct 14, 2014	New	$750,000	$750,000	23
Sep 25, 2014	New	$1,189,749	$1,189,749	7
Mar 11, 2014	New	$3,000,000	$3,000,000	24
Dec 3, 2013	New	$1,000,000	$934,923	7
Jun 14, 2013	New	$1,500,000	$595,000	27
May 8, 2013	New	$500,000	$416,000	8
Mar 27, 2013	New	$500,000	$489,583	19
Jul 26, 2012	New	$3,000,000	$1,204,152	33
Oct 28, 2011	New	$1,727,163	$1,727,163	38

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Nuclein, LLC

Biotechnology

Offering target: $26,114,842

Filed Oct 27, 2026